Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement: Hepatology

University of Alberta

$45,000.00

Characterization of inhibitory T cell signaling pathways in the duck hepatitis B model as potential targets of novel therapies for chronic viral hepatitis B

EF 2010-11

Résumé
Chronic hepatitis B affects over 350 million people worldwide and over 200 000 in Canada. Many of these chronic carriers die of complications of chronic liver disease and only a minority of patients with chronic hepatitis B achieves long-term control of infection with current therapies. The most important factor that predicts resolution or long-term control of hepatitis B is an effective response of the immune system against cells infected with the hepatitis B virus. However, in patients with chronic hepatitis B the function of the immune system that clears the hepatitis B infection is severely impaired. The goal of this fellowship is to study recently identified molecules that may contribute to the weakening of the immune response in an animal model of chronic hepatitis B and to explore strategies that are designed to restore an effective immune response as potential new therapies for chronic hepatitis B.
Programme
Fellowship - Priority Announcement: Hepatology
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
215885
Name
Yao Qingxia
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
The Canadian Association for the Study of Liver
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of inhibitory T cell signaling pathways in the duck hepatitis B model as potential targets of novel therapies for chronic viral hepatitis B
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Hepatology
Keyworddelim
Cellular Immune Response; Cytotoxic T-Lymphocyte Antigen 4 (Ctla-4/Cd152); Duck Hepatitis B Model; Hepatitis B Virus; Immunotheropy; Inhibitory T Cell Signalling; Interleukine-10 (Il-10); Persistent Viral Infection; Programmed Death 1 (Pd-1); T Cell Exhaustion
Abstract
Chronic hepatitis B affects over 350 million people worldwide and over 200 000 in Canada. Many of these chronic carriers die of complications of chronic liver disease and only a minority of patients with chronic hepatitis B achieves long-term control of infection with current therapies. The most important factor that predicts resolution or long-term control of hepatitis B is an effective response of the immune system against cells infected with the hepatitis B virus. However, in patients with chronic hepatitis B the function of the immune system that clears the hepatitis B infection is severely impaired. The goal of this fellowship is to study recently identified molecules that may contribute to the weakening of the immune response in an animal model of chronic hepatitis B and to explore strategies that are designed to restore an effective immune response as potential new therapies for chronic hepatitis B.
Competitiondate
201010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Yao, Qingxia
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $45,000~ $0~